BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

It looks like Simes is looking for employment.

Any company considering employing his services, would be wise wait and see how the ANI merger works out for former Biosante shareholders, including what return we see from Libigel, Elestrin and Bio-t-gel.

Stephen Simes' Experience

President | CEO | Board Director
Pharma | Biotech Companies
July 2013 – Present (1 month) Greater Chicago Area

After successfully closing our merger, I am seeking a new CEO role as well as board appointments with companies in the pharmaceutical, biotechnology, and life sciences industries.

However his summary and core competencies are interesting.

Public company CEO and Board Director with a proven track record of drug approvals, financings, and business development transactions. Extensive experience in formulating and implementing corporate strategies, establishing growth metrics, driving performance, and meeting growth objectives through both organic expansion and strategic acquisitions and partnerships.

Core Competencies:

- Experienced board member of both private and public companies

- P&L management, strategic planning and “hands-on” operations

- Deep knowledge in clinical drug development (Phase I – Phase IV)

- FDA regulatory pathways for clinical development and approval (e.g., Elestrin™ and LibiGel®)

- Raised over $250 million in corporate equity financing, and M&A

- Business development and product licensing

- Managing large scale clinical studies involving 3,000+ participants

- Women’s health, male and female hormone therapy, oncology, urology, growth disorders

What phase IV product did he gain his knowledge?

In order to be remotely successful the $250 million in equity financing translating into 43 % of the merged company would mean the Market Cap should be well over $580 million. Over $10 pps at today's outstanding share total. That only breaks even, not a success.

Time will tell whether his assertions are accurate. But at the moment some claims appear premature.